NCT04363242进行中（未招募）1 期
A Phase 1 Dose Escalation Trial of SYN125 Single Agent in Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Epithelial Cancers With EGFR Expressions.
Synermore Biologics Co., Ltd.8 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2020年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 22
- 试验地点
- 8
- 主要终点
- Part A: Incidence of dose-limiting toxicities (DLTs)
研究概览
简要总结
A Phase 1 Dose Escalation Trial of SYN125 Single Agent in the Treatment of Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Cancer of the Internal or External Lining of the Body.
详细描述
Humans have an immune system that can protect and fight infections and abnormal cells. T-cells are a type of cell produced by the body that can attack and kill cancer cells. Unfortunately, many cancer cells have ways preventing T-cells from working properly. SYN125 and SYN004 can make T-cells work again. This is a study to find the maximum tolerated dose of SYN125 when it is used as a single treatment (Part A) for solid tumors, and when it is used as a combined treatment with a fixed dose of SYN004 (Part B), in patients with epithelial cancers with EGFR (epithelial growth factor receptor) expressions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form.
- •Have documented diagnosis of recurrent or metastatic solid tumors for whom no standard treatment options are available (Part A only).
- •Have epithelial cancers which have endothelial growth factor receptor (EGFR) expressions (not necessarily mutated or over-expressed) (Part B only).
- •Note: Prior EGFR (epidermal growth factor receptor) therapy and approved checkpoint inhibitor therapy are allowed but not required.
- •Prior anti-PD-1 (programmed cell death 1), anti-PD-L1 (programmed death-ligand 1), anti-PD-L2 (programmed death-ligand 2), anti-cytotoxic T-lymphocyte antigen (CTLA-4) are allowed, where the wash-out period will be 28 days from last dose of previous therapy except for palliative RT and smaller molecular oral therapeutic agents where 5 half-lives or 28 days, whichever is shorter, will apply (Part A and Part B).
- •Have evaluable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for immune based therapeutics (iRECIST).
- •Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to
- •Adequate bone marrow function, with absolute neutrophil count >1,500/µL, platelet count >75,000/µL, and hemoglobin >9g/dL (or 5.6 mmol/L).
- •Adequate liver function with bilirubin <1.5 x the upper limit of normal (ULN) range, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 x the ULN.
- •Adequate renal function, as defined by having creatinine clearance ≥30 mL/min calculated by either Cockcroft-Gault or Modification of Diet in Renal Disease equations.
- •Adequate cardiac function, no clinically significant abnormalities assessed by electrocardiogram (ECG), and absence of significant cardiac disease.
- •Negative serum pregnancy test within 24 hours prior to start of study drug in female patients of childbearing potential. Not applicable to patients unable to become pregnant, including those with bilateral oophorectomy and/or hysterectomy or postmenopausal.
- •Patients of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (at least 1 of which must be a barrier method) during heterosexual intercourse, starting at screening and continuing throughout study, for a total of 31 weeks post-treatment completion.
排除标准
- •Have ongoing toxicities >Grade 1 according to NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v5.0 (excluding alopecia and neuropathy).
- •Have any contraindications to receiving cetuximab therapy, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 (anti-cytotoxic T-lymphocyte antigen) antibody, or other antibody or drug targeting T-cell co-stimulation or immune checkpoint pathways.
- •Have known hypersensitivity to study drugs.
- •Have undergone surgery and not recovered adequately from toxicities and/or complications from the intervention prior to starting study therapy; or have unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment.
- •Have clinically significant cardiac arrhythmia, unless well-controlled.
- •Have clinically active central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated brain or meningeal metastasis may participate and be eligible for treatment provided they are stable and asymptomatic, and have no evidence of new or enlarging brain metastases evaluated within 4 weeks prior to the first dose of study drug.
- •Patients with history of human immunodeficiency virus (HIV) and:
- •CD4+ T-cell count is ≤350 cells µL;
- •History of AIDS-defining opportunistic infection within the past 12 months;
- •Antiretroviral therapy <4 weeks and HIV viral load >400 copies/mL.
- •Have participated in another investigational drug or device study within 4 weeks of the first dose of study drug.
- •Female patient who is pregnant or breast feeding.
- •Have signs or symptoms of organ failure, major chronic illnesses other than cancer, or any concomitant medical or social condition that, in the opinion of the investigator, make it undesirable for the patient to participate in the study, or that could jeopardize compliance with the protocol.
- •Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
Part A: Incidence of dose-limiting toxicities (DLTs)
时间窗: Up to Day 28
Incidence of DLTs with single agent SYN125
Part B: Incidence of dose-limiting toxicities (DLTs)
时间窗: Up to Day 28
Incidence of DLTs with SYN125 and fixed-dose SYN004 administered in combination
次要结局
- Area under the serum concentration-time curve from time zero extrapolated to infinity (AUC0-inf)(Up to Day 106)
- Incidence of Clinical Laboratory Abnormalities(Up to Day 50)
- Serum concentration time profiles (Area under the serum concentration-time curve from time zero to the last measurable concentration)(Up to Day 106)
- Area under the serum concentration time-curve over the dosing interval(Up to Day 106)
- Maximum Observed Plasma Concentration (Cmax)(Up to Day 106)
- Time to maximum observed serum concentration (Tmax)(Up to Day 106)
- Terminal elimination half-life (t1/2)(Up to Day 106)
- Incidence of Adverse Events (AEs)(Up to Day 50)
- Clearance(Up to Day 106)
- Volume of distribution at steady-state (Vss)(Up to Day 106)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy SubjectsAlzheimer DiseaseNCT04920786TrueBinding, Inc.48
Unknown
1 期
Study of Safety and Biomarker Efficacy of TS23 in Healthy VolunteerThrombosisCerebral IschemiaMyocardial InfarctionVenous ThrombosisPulmonary EmbolismNCT03001544Translational Sciences, Inc.24
已完成
1 期
Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid TumorsColon Cancer, Breast Cancer, Cancer of the Head and NeckNCT02391727Synermore Biologics Co., Ltd.10
终止
1 期
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After SurgeryColorectal NeoplasmsNCT00041691Gilead Sciences30
已完成
1 期
First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer PatientsSolid TumorsNCT02277717Byondis B.V.185